| Kelly Jean Cushing, DO | |
|
4747 Arapahoe Ave, Boulder, CO 80303-1133 | |
| (303) 415-7610 | |
| (303) 415-7618 |
| Full Name | Kelly Jean Cushing |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 20 Years |
| Location | 4747 Arapahoe Ave, Boulder, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710910831 | NPI | - | NPPES |
| 500622186 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | DR.0056124 (Colorado) | Primary |
| 207Q00000X | Family Medicine | DR.0056124 (Colorado) | Secondary |
| 207Q00000X | Family Medicine | DO27740 (Oregon) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boulder Community Health | Boulder, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boulder Community Health | 6800707233 | 212 |
News Archive
A new national survey from the American Society of Anesthesiologists finds physician anesthesiologists are being forced out of network as insurance companies terminate their contracts, often with little or no notice.
CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.
Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.
Researchers have developed a novel device that improves stress urinary incontinence in men who have undergone prostatectomy, report researchers.
Outbreaks of filovirus haemorrhagic fevers (FHFs) such as those caused by the Ebola and Marburg viruses can only be controlled if agencies have the support and trust of local communities, according to two papers just published in the online edition of the Journal of Infectious Diseases as part of a special supplement on filovirusues.
› Verified 7 days ago
| Entity Name | Boulder Community Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821074196 PECOS PAC ID: 6800707233 Enrollment ID: O20040123000284 |
News Archive
A new national survey from the American Society of Anesthesiologists finds physician anesthesiologists are being forced out of network as insurance companies terminate their contracts, often with little or no notice.
CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.
Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.
Researchers have developed a novel device that improves stress urinary incontinence in men who have undergone prostatectomy, report researchers.
Outbreaks of filovirus haemorrhagic fevers (FHFs) such as those caused by the Ebola and Marburg viruses can only be controlled if agencies have the support and trust of local communities, according to two papers just published in the online edition of the Journal of Infectious Diseases as part of a special supplement on filovirusues.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Jean Cushing, DO 5450 Western Ave, Boulder, CO 80301-2709 Ph: (303) 415-7610 | Kelly Jean Cushing, DO 4747 Arapahoe Ave, Boulder, CO 80303-1133 Ph: (303) 415-7610 |
News Archive
A new national survey from the American Society of Anesthesiologists finds physician anesthesiologists are being forced out of network as insurance companies terminate their contracts, often with little or no notice.
CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.
Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.
Researchers have developed a novel device that improves stress urinary incontinence in men who have undergone prostatectomy, report researchers.
Outbreaks of filovirus haemorrhagic fevers (FHFs) such as those caused by the Ebola and Marburg viruses can only be controlled if agencies have the support and trust of local communities, according to two papers just published in the online edition of the Journal of Infectious Diseases as part of a special supplement on filovirusues.
› Verified 7 days ago
Naomi Y Feiman, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 4745 Arapahoe Ave Ste 310, Boulder, CO 80303 Phone: 303-442-2913 | |
Dr. Kartik Patel, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1942 Broadway Ste 314c, Boulder, CO 80302 Phone: 206-801-1656 | |
Alyse Power, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5377 Manhattan Cir Ste 103, Boulder, CO 80303 Phone: 720-273-3568 | |
Tara M Snow, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4747 Arapahoe Ave, Boulder, CO 80303 Phone: 303-415-7610 Fax: 303-415-7618 | |
Diana L Mancini, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4747 Arapahoe Ave, Boulder, CO 80303 Phone: 303-415-7610 Fax: 303-415-7618 |